Sustained response to salvage therapy for dabrafenib-resistant metastatic Langerhans cell sarcoma

Ann Oncol. 2016 Dec;27(12):2305-2307. doi: 10.1093/annonc/mdw299. Epub 2016 Aug 8.

G Lorillon¹, S Mourah^{2

3}, L Vercellino⁴, C de Margerie-Mellon⁵, C Pagès⁶, L Goldwirt², C Lebbe^{3

6}, J Tost⁷, A Tazi^{8

9}

¹ Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, National Reference Center for Langerhans cell histiocytosis, Pulmonology Department, Paris, France.
² Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Pharmacology and Genetic Department, Paris, France.
³ Univ Paris-Diderot, Sorbonne Paris Cité; INSERM U976, Paris, France.
⁴ Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Nuclear Medicine Department, Paris, France.
⁵ Univ. Paris-Diderot, Sorbonne Paris Cité; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Radiology Department, Paris, France.
⁶ Assistance Publique-Hôpitaux de Paris, Dermatology Department, Paris, France.
⁷ Laboratory for Epigenetics and Environment, Genotyping National Center, CEA-Genomic Institute, Evry, France.
⁸ Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, National Reference Center for Langerhans cell histiocytosis, Pulmonology Department, Paris, France [email protected].
⁹ Univ Paris-Diderot, Sorbonne Paris Cité; CRESS INSERM U1153, Biostatistics and Clinical Epidemiology Research Team, Paris, France.

No abstract available

Publication types